Humanin is a small protein that can protect brain cells from dying when they’re exposed to Alzheimer’s‑related problems like mutant genes and amyloid‑beta, but it doesn’t help with other kinds of cell damage. It works by blocking the death process itself, not by changing amyloid levels, so it could be used together with other Alzheimer’s treatments. However, the study doesn’t give dosing or safety info for people, so it’s still early‑stage research.

Neuronal cell death accounts for the clinical manifestations in Alzheimer's disease (AD). To establish the curative therapy of AD, neuroprotection is one of the primary therapeutic targets, and the elucidation of the mechanism of neuronal cell death is mandatory. Detailed characterization of neuronal cell death caused by familial AD (FAD)-linked mutant genes revealed that different cell death pathways are evoked by different types of mutants. Humanin (HN), a newly identified neuroprotective peptide, suppresses neuronal cell death caused by all known FAD mutants and A beta, while it has no effect on neuronal cell death caused by AD-irrelevant insults. The functional target of HN is the antagonism to neuronal death, not the modulation of A beta production, suggesting that HN-based medication can be combined with other remedies targeting A beta. HN is a promising seed for a novel therapy aiming at complete cure of AD through the suppression of neuronal loss.